Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Viela Bio stock

Learn how to easily invest in Viela Bio stock.

Viela Bio Inc is a biotechnology business based in the US. Viela Bio shares (VIE) are listed on the NASDAQ and all prices are listed in US Dollars. Viela Bio employs 170 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Viela Bio

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – VIE – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Viela Bio stock price (NASDAQ: VIE)

Use our graph to track the performance of VIE stocks over time.

Viela Bio shares at a glance

Information last updated 2021-05-14.
52-week range$21.30 - $53.83
50-day moving average $53.07
200-day moving average $39.12
Wall St. target price$53.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-78.90

Buy Viela Bio shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Viela Bio stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Viela Bio financials

Revenue TTM $11.7 million
Gross profit TTM $9.6 million
Return on assets TTM -23.83%
Return on equity TTM -41.26%
Profit margin 0%
Book value $-293.22
Market capitalisation $2.9 billion

TTM: trailing 12 months

Shorting Viela Bio shares

There are currently 1.9 million Viela Bio shares held short by investors – that's known as Viela Bio's "short interest". This figure is 9.6% down from 2.1 million last month.

There are a few different ways that this level of interest in shorting Viela Bio shares can be evaluated.

Viela Bio's "short interest ratio" (SIR)

Viela Bio's "short interest ratio" (SIR) is the quantity of Viela Bio shares currently shorted divided by the average quantity of Viela Bio shares traded daily (recently around 1.8 million). Viela Bio's SIR currently stands at 1.09. In other words for every 100,000 Viela Bio shares traded daily on the market, roughly 1090 shares are currently held short.

However Viela Bio's short interest can also be evaluated against the total number of Viela Bio shares, or, against the total number of tradable Viela Bio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Viela Bio's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Viela Bio shares in existence, roughly 30 shares are currently held short) or 0.0788% of the tradable shares (for every 100,000 tradable Viela Bio shares, roughly 79 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Viela Bio.

Find out more about how you can short Viela Bio stock.

Viela Bio share dividends

We're not expecting Viela Bio to pay a dividend over the next 12 months.

Viela Bio overview

Viela Bio, Inc. , a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company's lead product candidate is inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder; and which is in Phase III trials for patients with myasthenia gravis and IgG4-related diseases, as well as in Phase II trial for kidney transplant desensitization. It is also developing VIB4920 that is in Phase II trial for kidney transplantation rejection and rheumatoid arthritis, as well as in Phase IIb trial for sjögren's syndrome; and VIB7734, which is in Phase Ib trial for cutaneous lupus erythematosus, in Phase I trial for COVID-19-related acute lung injury, and a planned Phase II tria for systemic lupus erythematosus. The company's pre-clinical research and development product candidates include VIB1116 to decrease the number and function of antigen-presenting dendritic cells; and a mAb cytokine fusion protein to inhibit inflammatory responses. Viela Bio, Inc. has a strategic collaboration with Hansoh Pharmaceutical Group Company Limited and Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases in China, Hong Kong, Macau, Japan, Thailand, South Korea, Indonesia, Vietnam, Malaysia, the Philippines, Singapore, and Taiwan.

Viela Bio in the news

There are no recent company news

Frequently asked questions

What percentage of Viela Bio is owned by insiders or institutions?
Currently 55.079% of Viela Bio shares are held by insiders and 47.165% by institutions.
How many people work for Viela Bio?
Latest data suggests 170 work at Viela Bio.
When does the fiscal year end for Viela Bio?
Viela Bio's fiscal year ends in December.
Where is Viela Bio based?
Viela Bio's address is: One MedImmune Way, Gaithersburg, MD, United States, 20878
What is Viela Bio's ISIN number?
Viela Bio's international securities identification number is: US9266131005
What is Viela Bio's CUSIP number?
Viela Bio's Committee on Uniform Securities Identification Procedures number is: 926613100

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site